Preparation of [177Lu]PSMA-617 Using Carrier Added (CA) 177Lu for Radionuclide Therapy of Prostate Cancer
Objective: Lutetium-177 labelled PSMA-617 is an emerging radiopharmaceutical for targeted
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Objective: Lutetium-177 labelled PSMA-617 is an emerging radiopharmaceutical for targeted
Background: Cisplatin based chemoradiation forms the standard treatment for locally advanced head
For authors and organisers
Find the right journal for your paper and submit your manuscript.